Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 20/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861578 | 1.00 | ADAM17 (0.87) | ADAM17 | |
| SCHEMBL3861584 | 1.00 | ADAM17 (0.87) | ADAM17 | |
| SCHEMBL3860762 | 0.93 | ADAM17 (1.00) | ADAM17 | |
| SCHEMBL3860752 | 0.93 | ADAM17 (1.00) | ADAM17 | |
| SCHEMBL3860741 | 0.93 | ADAM17 (1.00) | ADAM17 | |
| SCHEMBL3860763 | 0.93 | ADAM17 (0.77) | ADAM17 | |
| SCHEMBL3860449 | 0.92 | ADAM17 (0.75) | ADAM17 | |
| SCHEMBL3860485 | 0.92 | ADAM17 (0.75) | ADAM17 | |
| Hydroxyamine SCHEMBL3870614 | 0.91 | ADAM17 (0.73) | ADAM17 | |
| Hydrochloric Acid SCHEMBL3864290 | 0.90 | ADAM17 (0.77) | ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595327-B2 | Exo-N-Hydroxy-3-[methyl({4-[(2-methylquinolin-4-yl) methoxy]phenyl}sulfonyl)amino]bicyclo[2.2.1]heptane-2-carboxamide; rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, ankylosing spondylitis, psoriasis, osteoarthritis, tumor metastasis, sepsis, AIDS, ulcerative colitis, multiple sclerosis | WYETH (US) | 2009-09-29 | — | — | US | disclosed |
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | WYETH (US) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211730-A1 | Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase | SI, MMP12, TNF | ADAM17 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.